Biogen (BIIB)

The methods disagree: one places the value today above the price ($229) and the other below.

Today — expensive, no margin of safety: at $229 trades ~10.0% above its value discounted to today (~$209); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — Preserva valor: the target price ($260) plus dividends yield just enough to preserve nominal capital, below the required 4% floor.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$129.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($229) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (0.4%/year) than we project (5.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$1.5 bn of owner earnings in year 5 (vs ~$1.9 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Year 0 = TTM to 30-Jun-2026, re-based from levels (FY2025 + cumulative H1'26 − cumulative H1'25) using the earnings 8-K of 2026-07-29, because XBRL has not yet ingested that quarter. The year-0 net margin and the path are normalized: they exclude integration/transaction charges from the Apellis acquisition (closed 14-May-2026), the litigation charge of ~US$105M in cost of sales, restructuring and the charges for acquired IPR&D and milestones, which are non-recurring by nature and distort GAAP earnings for the period (GAAP TTM net income of only US$0.835bn on an 8.3% margin, well below adjusted earnings). The margin anchor uses as its reference the underlying non-GAAP EPS guidance of July 2026 (US$15.85-16.85, midpoint ~US$16.35, before the IPR&D charges and the Apellis dilution, which the company itself treats as transitory), applied on a declining basis toward year 0 because the TTM still carries only ~1.5 months of Apellis integration and the bulk of the transaction costs. Revenue growth starts at +6% (year 1), above the +5% of «mid single digit» guided for calendar year 2026, because the +1y rolling window (Jul-2026 to Jun-2027) captures twelve months of SYFOVRE/EMPAVELI while the FY2026 guidance captures only ~7.5 months from the closing of the acquisition — a mechanical calendar effect, not an upward revision of the underlying business. The path decays smoothly toward +4% in year 5, reflecting the mix between the structural decline of the multiple sclerosis franchise (TECFIDERA generics, a TYSABRI biosimilar in Europe) and the double-digit growth of the Growth Portfolio (SKYCLARYS, QALSODY, ZURZUVAE, SYFOVRE, EMPAVELI, LEQEMBI). The base case exit multiple (14x, the floor of the pharma band [14,22]) reflects the eroding direction of the moat in the legacy segment and the ROIC structurally compressed by the goodwill/intangibles of the recent acquisitions (Apellis, Alcyone), without penalizing the base case below the band.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $260 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $229, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $260 in 5 years and a required return of 4.5% annually, the maximum to pay today is $209. Against the current market price ($229), the margin of safety is -10.0% (trades above the maximum → a premium is paid) and the total return at that price would be 2.5% annually.

• Multiple vs. the archetype band. The base-case exit multiple sits at the floor of the pharma band [14,22] due to the eroding direction of the legacy moat.
• Price vs. Market recognition. The market already recognizes much of the Growth Portfolio's strength.
• GAAP vs. adjusted earnings gap. TTM GAAP earnings materially understate normalized adjusted earnings due to non-recurring Apellis integration charges.
• Expected 5-year return. +3% of annual growth in the base case relative to the market price.
• Margin of safety today. No margin of safety: at this price capital is preserved, but it is not bought below its value.
• Sensitivity to the terminal multiple. The 5-year value is sensitive to the multiple holding at the floor of the band and not compressing further if erosion of the legacy portfolio accelerates.
• Dividend. Pays no dividend; the entire expected return depends on price appreciation.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✕ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (174%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Cash generation. TTM operating cash flow (~US$2.9bn) remains positive despite GAAP earnings depressed by integration charges.
• ROIC vs. the 10% bar. Compressed by invested capital that already carries the goodwill/intangibles from Apellis and Alcyone; the earnings numerator does not yet reflect the capital paid.
• GAAP earnings quality. GAAP earnings TTM are heavily depressed by non-recurring charges (Apellis integration, litigation, restructuring), well below normalized adjusted earnings.
• Capex intensity. Modest capex (TTM ~US$0.18bn on ~US$10bn of revenue), consistent with a capital-light model supported by contract manufacturing for several products.
• Stock-based compensation. TTM SBC of approximately 2.9% of revenue, below materiality relative to flow (does not trigger the method's SBC trap).
• Reinvestment runway. A late-stage pipeline with five upcoming registrational readouts, plus an active pattern of complementary M&A in rare disease and immunology.
• Leverage after Apellis. Total debt rose to approximately US$8.1bn after financing the acquisition, with net debt of ~US$6.8bn at the close of the second quarter of 2026.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

The drivers show the business's structural transition: multiple sclerosis declines steadily while rare disease and the Growth Portfolio as a whole grow at a double-digit rate. The Growth Portfolio combines direct product sales (volume × price, like any pharmaceutical product) with the LEQEMBI collaboration, monetized as a 50% share of the product's net profit co-commercialized with Eisai, not as direct sales — a different mechanism from its other products.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Growth Portfolio growth. The Growth Portfolio grew 24% year over year in the second quarter of 2026 and already exceeds the legacy portfolio in revenue.
• Legacy portfolio decline. Multiple sclerosis fell 13% year over year in the second quarter of 2026 from generic and biosimilar competition.
• Contribution from recent M&A. SYFOVRE and EMPAVELI, added with the Apellis acquisition, already contributed US$127.8 million in their first partial quarter of consolidation.
• Late-stage pipeline. Five registrational readouts expected over the next four quarters (litifilimab, felzartamab, zorevunersen), with preliminary data from diranersen in Alzheimer's.
• Consolidated revenue guidance. The July 2026 guidance points to "mid-single-digit" growth for the full year, moderate against the Growth Portfolio's 24% due to the weight of the legacy portfolio.
• Dependence on partner execution. LEQEMBI's growth depends heavily on commercial decisions controlled by Eisai, creating friction that Biogen has disclosed.
• Risk of further substitution. More generic/biosimilar competition could accelerate the legacy portfolio's decline faster than modeled.

• Demand recurrence. Chronic treatments for serious diseases generate recurring demand, though subject to generic/biosimilar substitution in mature products.
• Product differentiation. Strong in rare disease (sole approved treatment in several indications); weak in the legacy multiple sclerosis franchise, already genericized.
• Pricing power. Limited by growing regulatory pressure (IRA, Medicare negotiation) and by the genericization of mature products.
• Operating leverage. The higher-margin Growth Portfolio scales on an already-installed commercial cost base, but the Apellis integration adds new operating expense in the short term.
• Behavior in recessions. Demand for therapies for serious diseases is relatively inelastic to the economic cycle, though sensitive to government reimbursement decisions.
• Product concentration. TYSABRI and SPINRAZA each exceeded 10% of revenue in the last three fiscal years, a meaningful concentration.
• Channel concentration. Two wholesale distributors accounted for 43.9% of gross product revenue in 2025, up from 36.9% in 2023.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• !Interest coverage (EBIT / interest)4.8x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 174% of ROIC
• ✕Value creation (ROIC − 10% bar)-2pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.2x — no over-investment
• !Float / working capitalConsumes cash $0.1 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 2.9% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Net leverage. Net debt of approximately US$6.8bn at the close of the second quarter of 2026, after financing the Apellis acquisition partly with new debt.
• Cash position. Cash and equivalents fell from approximately US$4.2bn (including marketable securities) at year-end 2025 to US$1.3bn at the close of the second quarter of 2026, after the deal payment.
• Interest coverage. Net interest expense rose with the acquisition financing; the company guides to approximately US$0.85 per share of dilution in 2026 adjusted earnings per share from this item.
• Free cash flow generation. TTM free cash flow (OCF less capex) remains positive at approximately US$2.7bn despite the higher debt load.
• Maturity structure. US$800 million of the debt is the current portion at the close of the second quarter of 2026; before the Apellis financing, the company had no principal maturities between 2026 and 2029 and was in compliance with all its debt covenants.
• Legal and tax contingencies. Two material contingent liabilities not reserved on the balance sheet: an adverse Genentech judgment for approximately US$124.3 million in TYSABRI royalties (under appeal) and a German tax assessment of approximately US$246.5 million plus accruing interest (contested).

Who owns the shares — the alignment and whether there is a controlling shareholder.

• CEO track record. Viehbacher, in the role since November 2022, has executed a consistent portfolio repositioning via M&A and cost discipline.
• Capital allocation. Prioritizes reinvestment in R&D and complementary M&A over dividends or buybacks, consistent with a growth thesis in transition.
• Incentive alignment. Director and officer ownership as a group is low; no founder or controlling shareholder is identified in the proxy.
• M&A discipline. Recent acquisitions (Apellis, Alcyone) are aimed at strengthening existing therapeutic lines, not unrelated diversification, though the return outcome cannot yet be assessed given how recent the transactions are.
• Candor about risks. The company explicitly discloses the friction with Eisai over LEQEMBI and the dilution impact of the Apellis acquisition in its own guidance, without glossing over the near term.

• motivated-sellers
• one-off / restructuring that sinks GAAP
• recovery in progress

The "cheap" narrative does not fully apply: the market already recognizes much of the Growth Portfolio's strength. The gap between depressed GAAP earnings (Apellis integration charges, litigation, restructuring) and normalized adjusted earnings, guided to be several times higher, is the most concrete source of residual discount for anyone looking only at the GAAP multiple.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -15%/year (-55% total): the margin of safety protects the downside. The bull (+9%/year, +54% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Structural erosion of the multiple sclerosis franchise. TECFIDERA faces multiple generic entrants and lost its key European patent in November 2025; TYSABRI faces an approved biosimilar in the U.S. and the EU.
• Dependence on Eisai's execution in LEQEMBI. Biogen initiated international arbitration against Eisai in June 2025 over the allocation of commercialization responsibilities in Europe.
• U.S. regulatory pricing pressure. Medicare price negotiation under the Inflation Reduction Act already cut US$90 million net from 2025 revenue, with roughly three-quarters of the impact on the multiple sclerosis portfolio and one-quarter on SKYCLARYS; an eventual most-favored-nation pricing policy would widen the cut going forward.
• Distribution channel concentration. Two wholesale distributors accounted for 43.9% of gross product revenue in 2025, up steadily since 2023.
• Dependence on single-source suppliers. Certain manufacturing materials depend on single-source suppliers, including a sole supplier in China for certain SKYCLARYS inputs, with tariff exposure; replacing any of them would require time and regulatory approval.
• Binary late-stage pipeline risk. Five registrational readouts expected over the next four quarters (litifilimab, felzartamab, zorevunersen); a negative result would hit the future growth narrative that currently supports part of the multiple.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: narrow moat, eroding.

• Peter Lynch Growth at a reasonable price (GARP)

  A stalwart growing 5% at a multiple/growth of 4.9 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 3% (EBIT/EV) + ROIC 8% → falls outside the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts 0% vs our 5%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -15%/yr over 5y (material loss) → risk of permanent capital loss.

• Pat Dorsey Moat strength (Five Rules)

  A narrow moat, eroding; sources: intangibles, efficient scale, switching costs → fails the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting 0%, within what we project (5%) — the story squares with the numbers.